GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Intensity Therapeutics
Intensity Therapeutics is an oncology company. Its stock price is a bet on the success of its lead drug candidate. Its price is volatile and driven by news of clinical trials and partnerships that help fund its expensive development.
Share prices of companies in the market segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for direct injection into tumors that kill cancer cells and stimulate the immune response. We've categorized it as "Immuno-Oncology." The chart below shows the dynamics of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Intensity Therapeutics is an oncology company developing drugs that are administered directly to tumors to stimulate an immune response. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Intensity compares to it.
Change in the price of a company, segment, and market as a whole per day
INTS - Daily change in the company's share price Intensity Therapeutics
For Intensity Therapeutics, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Intensity Therapeutics is an immuno-oncology company, and its shares are driven by clinical trial news. The chart below shows average daily volatility for this biotech segment. It serves as a risk barometer against which investors should weigh extreme fluctuations in INTS shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Intensity Therapeutics is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Intensity Therapeutics
For Intensity Therapeutics, the year-over-year trend is a story about the development of its drug for direct tumor delivery. Its 12-month market cap depends entirely on clinical trial data, where it must prove that its approach can not only destroy local tumors but also stimulate a systemic immune response against metastases.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
As an early-stage biotech company, Intensity is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Intensity Therapeutics, an immuno-oncology company, exemplifies the binary nature of biotech investing. Its shares move not in sync with the market, but with the release of clinical trial data. Positive results lead to sharp outperformance, while negative results lead to a crash.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Intensity Therapeutics
Intensity Therapeutics is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its lead injectable therapy triggers an immediate and strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Intensity Therapeutics is a clinical-stage oncology company developing a new approach to cancer treatment that involves directly injecting drugs into tumors to destroy them and activate the immune system. The graph below shows the dynamics of the biotech sector, where the search for new immunotherapy methods continues.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Intensity Therapeutics is a clinical-stage biotech company developing a new approach to cancer treatment. Its shares are buoyed by anticipation of trial results. Positive data can trigger explosive growth, while failures can lead to a crash, and these events are in no way related to the overall state of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Intensity Therapeutics
Intensity Therapeutics is an oncology company developing drugs for direct injection into tumors. Its weekly stock price is volatile and depends on the results of clinical trials of this innovative therapeutic strategy.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Intensity Therapeutics develops immuno-oncology drugs. This chart is a tool for assessing how clinical trial news impacts the stock in the short term compared to the overall sector trend. Is the company's volatility a personal story?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Intensity Therapeutics is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
INTS - Market capitalization of the company Intensity Therapeutics
The Intensity Therapeutics chart is a curve of hope in immuno-oncology. Its market cap reflects investors' faith in a new approach to cancer treatment that involves injecting a drug directly into the tumor to stimulate an immune response. It's a highly volatile story, typical of biotech.
INTS - Share of the company's market capitalization Intensity Therapeutics within the market segment - Oncology immuno-therapy
Intensity Therapeutics is a biopharmaceutical company developing a new approach to cancer treatment that involves directly injecting a drug into the tumor to stimulate an immune response. In the immuno-oncology segment, its market capitalization reflects the potential of this innovative approach. The company's market capitalization reflects the success of its clinical trials.
Market capitalization of the market segment - Oncology immuno-therapy
Intensity Therapeutics is developing drugs for direct injection into tumors. How big is this arena? The chart below shows the pulse of the entire immuno-oncology sector. Its high volatility reflects both the enormous hopes for new cancer treatments and the high risk of clinical failure.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Intensity Therapeutics chart shows how the market is pricing this new approach to cancer treatment. The company's market cap is based on its technology for directly injecting drugs into tumors to stimulate an immune response. This chart is fraught with clinical risks, but it has the potential to change the paradigm in immuno-oncology.
Book value capitalization of the company, segment and market as a whole
INTS - Book value capitalization of the company Intensity Therapeutics
The book value of Intensity Therapeutics, an oncology company, is its tangible capital base, consisting of the rights to drug candidates developed using its unique technology and financial reserves for clinical trials. The chart below shows how this scientific and financial capital has changed.
INTS - Share of the company's book capitalization Intensity Therapeutics within the market segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company whose tangible assets are the research laboratories where its unique platform for direct drug delivery to tumors is being developed. The chart shows the share of this specialized R&D infrastructure the company controls.
Market segment balance sheet capitalization - Oncology immuno-therapy
Intensity Therapeutics is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Intensity focuses on drug development, and its capital comes from its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Intensity Therapeutics' assets are not factories, but capital invested in clinical trials of its drug candidate, which is injected directly into tumors to stimulate an immune response against cancer. Its book value reflects its financial resources for this approach.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Intensity Therapeutics
Intensity Therapeutics is developing a new form of immunotherapy that delivers drugs directly to tumors. Its market capitalization is a bet on this unique approach. The chart shows how investors view its clinical data and the potential of this technology.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Intensity Therapeutics develops drugs for direct delivery to tumors to stimulate an immune response. This is an innovative approach in oncology. The chart shows how the market evaluates the potential of this unique technology compared to its current assets.
Market to book capitalization ratio for the market as a whole
Intensity Therapeutics is developing a new approach to cancer treatment. Its market capitalization reflects investors' bet on the success of this unique approach. This chart illustrates how, in oncology, the life-saving potential and market size of a new drug generate a valuation that exceeds its stock price multiple times.
Debts of the company, segment and market as a whole
INTS - Company debts Intensity Therapeutics
Intensity Therapeutics is a clinical-stage oncology company developing drugs for direct tumor delivery. This innovative approach requires significant investment in clinical trials to prove its efficacy and safety. This chart shows how the company raises funding to support its costly research.
Market segment debts - Oncology immuno-therapy
Intensity Therapeutics is a clinical-stage oncology company developing a new approach to immunotherapy. Its future depends on the results of clinical trials. This chart shows its cash reserves and how long it can fund its expensive research without raising new capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Intensity Therapeutics
Intensity Therapeutics is a clinical-stage biopharmaceutical company developing cancer treatments. This chart shows its financial structure. For a biotech whose success is uncertain, debt is a significant burden. It diverts valuable resources from research, which is the only chance to create value.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Intensity Therapeutics is developing a new approach to cancer treatment by injecting drugs directly into tumors to stimulate an immune response. The chart shows the overall debt burden in the biotech sector, providing context for assessing how the company finances its innovative, yet risky and expensive, clinical trials.
Debt to book value of all companies in the market
Intensity Therapeutics is a clinical-stage oncology company developing a novel approach to cancer treatment. This chart clearly demonstrates that the debt market is closed to such innovative companies, which have not yet proven their commercial viability. Their survival and growth depend entirely on their ability to attract equity capital.
P/E of the company, segment and market as a whole
P/E - Intensity Therapeutics
For Intensity Therapeutics, a clinical-stage immuno-oncology company, the P/E ratio is irrelevant. It has no products or revenues. Its valuation on this chart is arbitrary. The company's true value is determined by investors' faith in the potential of its scientific platform to create a new generation of cancer drugs.
P/E of the market segment - Oncology immuno-therapy
Intensity Therapeutics is a clinical-stage oncology company developing a new class of drugs for direct injection into tumors that kill cancer cells and activate the immune response. This chart shows the average valuation for the sector, helping to understand how the market views this innovative approach to cancer treatment.
P/E of the market as a whole
Intensity Therapeutics is a biotech company developing drugs for direct injection into tumors to stimulate immune responses. Its valuation is a pure bet on the success of this innovative technology. It is in no way tied to the general economic cycles illustrated by this chart. Its fate is decided in the clinics.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Intensity Therapeutics
Intensity Therapeutics is a clinical-stage biotech company developing drugs for direct delivery to tumors to destroy them and stimulate an immune response. This chart reflects investor expectations for clinical trial results. The valuation is based on the potential of its technology to transform "cold" tumors into "hot" ones.
%20P%2FE%20Intensity%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Intensity-Therapeutics&v=1772612875241 "Chart of the company's future (projected) P/E Intensity Therapeutics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Intensity Therapeutics is a clinical-stage oncology company developing a new approach to immunotherapy through direct tumor delivery. Its valuation relative to other biotechs reflects investors' opinions on its unique technology. This is a bet that its method can make "cold" tumors visible to the immune system.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772612875252 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Intensity Therapeutics is an oncology company developing drugs for direct delivery to tumors to stimulate an immune response. This is an innovative approach in immuno-oncology. This chart shows the overall risk appetite of investors. For biotech companies with unconventional but promising technologies, a positive environment is important to attract attention and funding.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772612875270 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Intensity Therapeutics
Intensity Therapeutics is a clinical-stage oncology company developing a new approach to cancer treatment by directly injecting drugs into tumors to stimulate an immune response. The financial performance shown here reflects the costs of clinical trials for this innovative approach.
Profit of companies in the market segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for direct tumor delivery. This chart reflects the financial health of the immuno-oncology sector. It demonstrates the potential commercial success of innovative cancer treatment approaches and the high barriers to market entry for small biotech companies.
Overall market profit
Intensity Therapeutics is an oncology company developing drugs for direct delivery to tumors. This is an innovative approach in immuno-oncology. Like other clinical-stage biotechs, INTS is only interested in trial results. The economic cycles shown in this chart do not affect the need for cancer treatment.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Intensity Therapeutics
Intensity Therapeutics is an oncology company developing a new approach to cancer treatment by directly injecting drugs into tumors to stimulate an immune response. Its revenue forecast hinges on the success of this approach in clinical trials. This chart reflects analysts' confidence in the potential of its unique therapeutic platform.
%20profit%20of%20the%20company%20Intensity%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Intensity-Therapeutics&v=1772612875399 "Graph of future (projected) profit of the company Intensity Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Intensity Therapeutics is a biotech company developing drugs for direct tumor delivery that not only kill cancer cells but also activate the immune system to fight metastases. This graph shows the outlook for immuno-oncology. It illustrates the potential of innovative approaches that can transform "cold" tumors into "hot" ones, accessible to the immune system.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772612875441 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
For Intensity Therapeutics, a clinical-stage oncology company, this chart is an indicator of capital availability. Positive economic expectations increase investor willingness to finance risky but promising projects. A negative trend could make raising funds more difficult.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772612875497 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Intensity Therapeutics
Intensity Therapeutics is a clinical-stage oncology company. This metric, in the absence of sales, reflects pure faith in its scientific approach. Investors evaluate the potential of its drugs, not its current financial performance.
P/S market segment - Oncology immuno-therapy
Intensity Therapeutics is a biopharmaceutical company developing a new approach to immuno-oncology by directly delivering drugs to tumors to destroy them and stimulate an immune response. This chart shows the average valuation in the immunotherapy sector, reflecting investor expectations for the company's innovative platform.
P/S of the market as a whole
Intensity Therapeutics, Inc. is a clinical-stage oncology company developing drugs that are administered directly to tumors to stimulate an immune response. The company's valuation is based on the potential of this innovative approach. This chart helps estimate the market premium for new approaches in immuno-oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Intensity Therapeutics
Intensity Therapeutics develops drugs for direct delivery to tumors to destroy them and stimulate an immune response. Future revenue depends on the success of this new approach in oncology. The chart demonstrates investors' confidence in the potential of its technology to transform "cold" tumors into "hot" ones.
%20P%2FS%20Intensity%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Intensity-Therapeutics&v=1772612875650 "The graph of the company's future (projected) P/S Intensity Therapeutics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for direct delivery to tumors. Its technology is designed to destroy cancer cells while simultaneously stimulating an immune response against metastases. This chart shows how investors view the potential of this unique therapeutic strategy.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772612875709 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the immuno-oncology market. For Intensity Therapeutics, a company developing drugs for direct tumor delivery, this is an indicator of investment interest. Market optimism is helping fund the development of innovative approaches that can make "cold" tumors visible to the immune system.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772612875773 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Intensity Therapeutics
Intensity Therapeutics is a clinical-stage oncology company developing drugs for direct delivery to tumors to kill cancer cells and stimulate immune responses. This chart reflects revenue from partnerships. Future revenue is dependent on the success of clinical trials and the commercialization of its innovative immunotherapy approach.
Sales of companies in the market segment - Oncology immuno-therapy
Intensity Therapeutics is a clinical-stage oncology company developing drugs for direct delivery to tumors to destroy them and stimulate an immune response. This chart shows the growth of the cancer immunotherapy market. Intensity's unique approach can transform tumors into "vaccines" against themselves, representing a new frontier in cancer treatment.
Overall market sales
Intensity Therapeutics is a clinical-stage oncology company developing drugs for direct tumor delivery. Its growth depends on successful research. The overall economic situation, shown in this chart, impacts the availability of capital to fund innovative, yet risky, approaches to cancer treatment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Intensity Therapeutics
Intensity Therapeutics is an oncology company developing a new approach to cancer treatment that involves directly injecting a drug into tumors to stimulate an immune response. This graph reflects analysts' expectations for the success of clinical trials of this innovative immunotherapeutic strategy.
%20sales%20of%20the%20company%20Intensity%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Intensity-Therapeutics&v=1772612875975 "Schedule of future (projected) sales of the company Intensity Therapeutics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Intensity Therapeutics is developing drugs for direct injection into tumors to activate the immune response. This chart highlights expectations for the cancer immunotherapy sector. It illustrates the interest in new approaches that can transform "cold" tumors into "hot" ones, making them vulnerable to the immune system.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772612876002 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Intensity Therapeutics, Inc. is a clinical-stage oncology company developing a novel approach to cancer treatment by directly delivering drugs to tumors. Its future depends on the results of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital to finance innovative, but risky, approaches to cancer treatment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772612876045 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Intensity Therapeutics
Intensity Therapeutics is developing a new approach to cancer treatment by delivering drugs directly to tumors to stimulate an immune response. The chart shows the company's financial status during the clinical trials phase. Negative values represent investments in this innovative method, which could significantly improve the effectiveness of immunotherapy.
Market segment marginality - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for direct delivery to tumors to stimulate immune responses. For a company in the research stage, this chart serves as a benchmark. It shows the average profitability in their sector, illustrating the financial potential that could be realized if their therapy is successful and commercialized.
Market marginality as a whole
Intensity Therapeutics is a clinical-stage oncology company developing drugs for direct tumor delivery. This overall market profitability curve is irrelevant to the company. Its future depends solely on the results of clinical trials and the ability to prove that its approach can make "cold" tumors susceptible to immunotherapy.
Employees in the company, segment and market as a whole
Number of employees in the company Intensity Therapeutics
Intensity Therapeutics is a pharmaceutical company developing a new approach to cancer treatment by directly delivering drugs to tumors. This graph shows a small team managing late-stage clinical trials. Their focus is on obtaining regulatory approval.
Share of the company's employees Intensity Therapeutics within the market segment - Oncology immuno-therapy
Intensity Therapeutics is developing a new approach in immuno-oncology, delivering drugs directly into tumors to stimulate an immune response. This chart shows the percentage of leading oncologists and immunologists working on this innovative approach that the company is attracting. It reflects its unique concentration of scientific expertise.
Number of employees in the market segment - Oncology immuno-therapy
Intensity Therapeutics is a biopharmaceutical company developing a new approach to cancer treatment that involves administering a drug directly to the tumor to stimulate an immune response. This graph demonstrates how focused and innovative approaches to oncology have become, requiring scientists to have a deep understanding of immunology.
Number of employees in the market as a whole
Intensity Therapeutics, an immuno-oncology company, is developing a new approach to cancer treatment. The biopharmaceutical sector is one of the most research-intensive and competitive. This graph illustrates the overall picture, but within it, there is intense competition for scientific breakthroughs and the best talent capable of achieving them.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Intensity Therapeutics (INTS)
Intensity Therapeutics is a biotech company developing drugs for direct injection into tumors. This chart is a classic example of intellectual capital valuation. The company's value is based on market expectations for its lead drug candidate. The chart shows the high future value the market is pricing into this development.
%20of%20the%20company%20Intensity%20Therapeutics%20(INTS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Intensity-Therapeutics-INTS&v=1772612876320 "Chart of market capitalization per employee (in thousands of dollars) of the company Intensity Therapeutics (INTS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Intensity Therapeutics is developing a new approach to immuno-oncology by delivering drugs directly to tumors. The chart shows how investors are betting on their unique technology and team of scientists. A comparison with the industry allows us to assess how breakthrough and promising their cancer treatment method is considered.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772612876325 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Intensity Therapeutics is a biopharmaceutical company developing a novel approach in immuno-oncology. This chart shows the average market value generated by one specialist, highlighting how the market values innovative scientific concepts.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772612876355 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Intensity Therapeutics (INTS)
Intensity Therapeutics is a clinical-stage biotech focused on oncology. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company burns per scientist on R&D.
%20Chart%20Intensity%20Therapeutics%20(INTS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Intensity-Therapeutics-INTS&v=1772612876370 "Company Profit Per Employee (in thousands of dollars) Chart Intensity Therapeutics (INTS)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for direct injection into tumors to stimulate an immune response. It is a research-intensive business in clinical trials. The negative profit per employee, which this chart likely shows, is typical for biotech and reflects the high costs of its research team and development.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772612876413 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Intensity Therapeutics (INTS) is a clinical-stage biotech developing drugs (INT230-6) for *injection* directly into tumors to kill them from the inside and activate the immune system. This is an R&D business. This chart shows the average profitability per employee across the market. For INTS (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772612876466 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Intensity Therapeutics (INTS)
Intensity Therapeutics is a clinical-stage immuno-oncology company. This chart reflects the company's path to commercialization. The current low values are typical for biotech companies in the R&D phase, but they could rise sharply if clinical trials are successful and the drug is brought to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Intensity-Therapeutics-INTS&v=1772612876478 "Sales chart per company employee Intensity Therapeutics (INTS)")
Sales per employee in the market segment - Oncology immuno-therapy
Intensity Therapeutics is a clinical-stage biotech company developing drugs for direct tumor injection (immuno-oncology). Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies.
Sales per employee for the market as a whole
Intensity Therapeutics is a clinical-stage biotech company developing drugs for direct tumor injection (immuno-oncology). The company has no commercial products or revenue. This metric is irrelevant. Its entire value lies in the potential of its R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Intensity Therapeutics (INTS)
Intensity Therapeutics is an oncology company developing a drug that is injected directly into tumors to stimulate an immune response. This chart shows the odds that their technology will fail. "Bears" believe this approach (intratumoral injection) will be ineffective or have no advantage.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Intensity-Therapeutics-INTS&v=1772612876562 "Short Shares Chart for the Company Intensity Therapeutics (INTS)")
Shares shorted by market segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for direct injection into tumors (intratumoral) to kill cancer cells and stimulate an immune response. This chart reflects the total short position in the immuno-oncology sector. High values indicate general investor skepticism about the success of clinical trials of new, unproven treatments.
Shares shorted by the overall market
Intensity Therapeutics is a clinical-stage oncology company developing drugs for direct injection into tumors. This chart illustrates the overall market pessimism. When fear dominates, investors are unwilling to take the risk of unsuccessful clinical trials. They are selling INTS shares, fearing the company will not have enough capital to complete R&D in a market panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Intensity Therapeutics (INTS)
Intensity Therapeutics is an oncology company developing drugs that are injected directly into tumors to "train" the immune system to attack cancer. This chart tracks how investors view their clinical data, showing "overheated" (above 70) on positive news or "oversold" (below 30) when there are delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Intensity-Therapeutics-INTS&v=1772612876707 "RSI 14 indicator chart for the company's stock Intensity Therapeutics (INTS)")
RSI 14 Market Segment - Oncology immuno-therapy
Intensity Therapeutics is an oncology company developing drugs for "direct tumor injection" (intratumoral). Their technology aims to destroy tumors from the inside and activate the immune response. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For Intensity Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is shut off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INTS (Intensity Therapeutics)
Intensity Therapeutics is an oncology company developing drugs for direct (intratumoral) delivery to tumors to kill them while simultaneously activating the immune system. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INTS-Intensity-Therapeutics&v=1772612876890 "A chart showing analyst consensus forecasts for the expected stock price. INTS (Intensity Therapeutics)")
The difference between the consensus estimate and the actual stock price INTS (Intensity Therapeutics)
Intensity Therapeutics is an oncology company whose drug (INT230-6) is injected *directly into the tumor* to kill it from the inside and train the immune system. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this innovative R&D approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INTS-Intensity-Therapeutics&v=1772612876963 "A chart showing the difference between the consensus forecast and the actual stock price. INTS (Intensity Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Intensity is an R&D biotech company developing drugs that are injected "directly into the tumor" to "teach" the immune system to attack cancer throughout the body. This chart reflects analysts' overall expectations for the immunotherapy sector. It shows whether experts believe in the success of "injections into the tumor."
Analysts' consensus forecast for the overall market share price
Intensity Therapeutics is a biotech company developing drugs that are administered directly to tumors (intratumorally) to destroy them and activate the immune system. This chart reflects the overall market "risk appetite." For INTS, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Intensity Therapeutics
Intensity Therapeutics is a biotech R&D company focused on immuno-oncology. Their signature drug (INT230-6) is administered directly into the tumor (intratumorally) to kill it from the inside while simultaneously training the immune system to attack metastases. This graph is a clear indicator of faith in their R&D, reflecting their (very risky) progress in clinical trials.
AKIMA Market Segment Index - Oncology immuno-therapy
Intensity Therapeutics (INTS) is an oncology company developing drugs (INT230-6) for direct injection into tumors. Their goal is to kill the tumor from the inside while simultaneously training the immune system to attack metastases. The chart shows the segment's average index, helping investors assess how this direct-attack strategy compares to the overall market.
The AKIM Index for the overall market
Intensity Therapeutics is a biotech company that uses a proprietary delivery platform to deliver cytotoxic drugs directly to tumors. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this localized chemotherapy story compares to overall economic trends in oncology.
